{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":39,"searchCount":0},"additional":{"submitter":["Campos PE"],"funding":["European Research Council"],"pagination":["E350"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7401255"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(7)"],"pubmed_abstract":["Chemical study of the CH2Cl2-MeOH (1:1) extract from the sponge Haliclona sp. collected in Mayotte highlighted three new long-chain highly oxygenated polyacetylenes, osirisynes G-I (1-3) together with the known osirisynes A (4), B (5), and E (6). Their structures were elucidated by 1D and 2D NMR spectra and HRESIMS and MS/MS data. All compounds were evaluated on catalase and sirtuin 1 activation and on CDK7, proteasome, Fyn kinase, tyrosinase, and elastase inhibition. Five compounds (1; 3-6) inhibited proteasome kinase and two compounds (5-6) inhibited CDK7 and Fyn kinase. Osirisyne B (5) was the most active compound with IC50 on FYNB kinase, CDK7 kinase, and proteasome inhibition of 18.44 µM, 9.13 µM, and 0.26 µM, respectively."],"journal":["Marine drugs"],"pubmed_title":["Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge Haliclona sp."],"pmcid":["PMC7401255"],"funding_grant_id":["634674"],"pubmed_authors":["Gauvin-Bialecki A","Campos PE","Tintillier F","Trougakos IP","Clerc P","Chendo C","de Voogd NJ","Jerabek M","Le Goff G","Herbette G","Bignon J","Papanagnou ED","Ouazzani J"],"view_count":["39"],"additional_accession":[]},"is_claimable":false,"name":"Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge Haliclona sp.","description":"Chemical study of the CH2Cl2-MeOH (1:1) extract from the sponge Haliclona sp. collected in Mayotte highlighted three new long-chain highly oxygenated polyacetylenes, osirisynes G-I (1-3) together with the known osirisynes A (4), B (5), and E (6). Their structures were elucidated by 1D and 2D NMR spectra and HRESIMS and MS/MS data. All compounds were evaluated on catalase and sirtuin 1 activation and on CDK7, proteasome, Fyn kinase, tyrosinase, and elastase inhibition. Five compounds (1; 3-6) inhibited proteasome kinase and two compounds (5-6) inhibited CDK7 and Fyn kinase. Osirisyne B (5) was the most active compound with IC50 on FYNB kinase, CDK7 kinase, and proteasome inhibition of 18.44 µM, 9.13 µM, and 0.26 µM, respectively.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2024-11-07T07:52:37.963Z","creation":"2020-08-15T07:09:45Z"},"accession":"S-EPMC7401255","cross_references":{"pubmed":["32635268"],"doi":["10.3390/md18070350"]}}